Validation is paramount when working at scale. As antibodies stack across cycles, even one silent failure can produce a domino effect that impacts every cell phenotype in the dataset.
Image Credit:Shutterstock.com/Krot_Studio
However, the most widespread issue with antibodies in IHC studies is not an experiment that fails. Instead, it is a reasonably conducted experiment that silently generates the wrong answer.
An antibody that generates a compelling signal in the wrong cell type, or in the right cell type but the incorrect compartment, produces data that may look correct but is in fact not.
In single-plex IHC, a failure in validation impacts just one measurement. In a multiplex panel, however, it impacts every phenotype including that marker, which may be each and every cell type in the dataset.
Antibody failures are dangerous because they’re invisible. A failed antibody doesn't typically produce an image that is obviously wrong. Rather, it produces one that looks as though it could be correct.
Source: Atlas Antibodies AB
| Failure mode |
What the user sees |
What they think is happening |
What is actually happening |
| Cross-reactivity |
Strong, clean-looking signal
in the expected
compartment |
Antibody is working perfectly |
Antibody is binding a structurally similar off-target protein |
| Lot variation |
An intensity shift between experiments: either weaker or stronger than previous |
Protocol drift or operator
error |
The new antibody lot has different binding characteristics to the previous one |
| Over-concentration |
Nuclear protein appearing cytoplasmic; diffuse membranous staining |
Unexpected biology or fixation artifact |
Antibody saturating off-target sites due to excess concentration |
| FFPE incompatibility |
No signal on FFPE despite the confirmed expression; Western blot positive |
Poor antigen retrieval or degraded tissue |
Antibody validated only on non-fixed or denatured protein. The epitope is masked in FFPE |
| TSA bleed-through |
Signal appears in an adjacent channel without a corresponding antibody |
Spectral unmixing error or a scanner calibration issue |
Residual HRP activity or fluorophore emission overlap amplified by TSA sensitivity |
Antibody reproducibility challenges
Two antibody vials that share the same name and are from the same supplier can produce distinct staining intensities if they don’t come from the same production lot. Variation by lot is not an uncommon edge case: it is, in fact, the norm in antibody-based research, and is ultimately why lot number documentation should be considered scientific traceability rather than mere paperwork.
About Atlas Antibodies AB
Atlas Antibodies, founded on the Human Protein Atlas project, provides a comprehensive range of highly validated antibodies targeting over 75% of the human proteome. Core products include Triple A Polyclonals™ advanced rabbit polyclonal antibodies, and PrecisA Monoclonals™ precise mouse monoclonals designed for superior specificity.
Atlas Antibodies also offers PrEST Antigens™, recombinant protein fragments used for control experiments, and MolBoolean™, an innovative technology for in situ protein-protein interaction studies. Manufactured in Sweden and distributed globally, Atlas Antibodies’ products support diverse research applications with exceptional accuracy and reliability.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices, and treatments.